New Jersey’s highly educated workforce, high concentration of biopharmaceutical companies and an ecosystem that includes world-class research universities, hospitals and medical schools have made New Jersey a global life sciences hub.
Here are just a few of the companies that recently chose to locate or expansion their operations in New Jersey.
In May 2017, San Diego-based ACADIA Pharmaceuticals Inc. announced the opening of a new research and development office in Princeton. The biopharmaceutical company focuses on the development and commercialization of innovative medicines that address central nervous system disorders.
Allergan announced its plans to consolidate its New Jersey-based operations in Parsippany, Bridgewater, Jersey City and Rockaway into a new 431,495-square-foot U. S. headquarters in Madison in 2017. The U.S. subsidiary of the Dublin-based pharmaceutical company was awarded a $58.2 million Grow NJ tax incentive over 10 years for the creation of 300 new jobs and the retention of 1,019 more.
In August 2016, Aurobindo USA, broke ground for its new U.S. headquarters in East Windsor Township. The U.S. unit of the India-based global pharmaceutical company, Aurobindo Pharma Limited, is building a 567,000-square-foot headquarters facility that also will accommodate a new warehouse, distribution and manufacturing center for the manufacture and distribution of generic drugs.
BAP Pharma, a UK-based supplier of comparators for clinical trials, celebrated the official opening of its U.S. headquarters in April, 2016, in Landing. It is the company’s first U.S. location.
Bayer HealthCare established a new U.S. headquarters on a 94-acre campus in Whippany – a $250 million investment consolidating Bayer’s existing New York and New Jersey operations. The 700,000 square-foot-office space, which opened in October 2013, features state-of-the-art technology and a modern, open design for the approximately 2,400 employees now based at the new location.
In April 2017, Biocartis Group NV, a molecular diagnostics company based in Belgium, announced the establishment of its U.S. subsidiary, Biocartis US Inc., in New Jersey. Biocartis expects to begin the U.S. commercial roll-out of its rapid and fully automated Idylla platform with accompanying assays, with a focus on oncology research products in 2017.
BioFarma, an Italian company specializing in manufacturing probiotics and nutritional supplements, announced it was putting down roots in East Windsor in August 2017. A referral from SelectUSA, a US government-wide program housed in the International Trade Administration at the US Department of Commerce, the facility will open in late fall 2017. It represents a $6 million investment and will create 25 new jobs.
In October, 2015, Celgene Corp. completed the purchase of the former Merck research and development complex in Summit. The purchase gives Celgene an additional 650,000 square feet of office space and 450,000 square feet of R&D space, in addition to the 550,000-square-foot expansion of its global headquarters in Summit.
In April, 2016, Daiichi Sankyo announced the consolidation of its New Jersey facilities at a new U.S. headquarters in Basking Ridge. The global company’s employees are expected to begin moving into the 305,000-square-foot, three-building campus in 2017.
In May 2017, Evotec AG, a leading drug discovery alliance and development partnership company, celebrated the opening of its U.S. headquarters and the expansion of its facility in Princeton. Headquartered in Hamburg, Germany, the company partners with pharmaceutical and biotechnology companies, academia, patient advocacy groups and venture capitalists to rapidly progress the discovery and development of innovative drugs.
Switzerland-based Ferring Pharmaceuticals invested $135 million to expand its footprint in the New Jersey, opening a state-of-the-art U.S. operations center on a 25-acre lot in Parsippany. The center, which officially opened in December 2014, houses 275 employees, including management, administration, commercial operations, manufacturing and R&D. The company cited the availability of talented, highly-trained pharmaceutical professionals as a major factor for choosing New Jersey.
ForDoz Pharma, a company that researches, manufactures and develops new drug delivery platform processes, held a groundbreaking ceremony for its new facility in East Windsor in August 2017. The company currently occupies a 52,281-square-foot facility on the same site. The new facility is expected to be completed by next spring and gives the company the ability to increase their New Jersey workforce from 17 to 30.
Frontage Laboratories, the global pharmaceutical research company, opened its newest New Jersey facility in Secaucus in May 2015, with the aid of $2.44 million in Grow NJ incentives. The 36,000-square-foot facility, which includes a 160-bed research center, nearly tripled the company’s clinical capacity in the U.S. and complement its existing facility in Hackensack.
GLAXOSMITHKLINE CONSUMER HEALTHCARE
GlaxoSmithKine Consumer Healthcare held a ribbon cutting for its new location in Warren in April, 2016. The 109,000-square-foot facility will serve as the global company’s U.S. headquarters. It will accommodate approximately 900 employees in research and development, marketing, sales and supply chain management.
In April 2017, HIPRA, a Spanish multinational veterinary pharmaceutical company focused on biologics and vaccine products, selected the South Jersey Technology Park at Rowan University for its North American headquarters. HIPRA plans to build a 375,000-square-foot facility to accommodate its office, research and development, manufacturing, warehouse and distribution facilities on a 25-acre site on Rowan’s West Campus in Mantua Township, opening the door to research collaborations with Rowan University’s science and engineering faculty and students.
In September, 2015, Portuguese pharmaceutical manufacturer, Hovione, announced its plans to expand its East Windsor manufacturing facility by 30,600 square feet to accommodate its growth. In March, 2016, the company announced a partnership with Vertex Pharma to set up a continuous manufacturing facility in East Windsor. The project is expected to be completed in 2017.
After the Hurel Corporation outgrew its space at the New Jersey Economic Development Authority’s Commercialization Center for Innovative Technologies (CCIT) in 2016, the growing biotechnology company leased just over 5,000 square feet of wet lab space at the Biotechnology Development Center II on the Technology Centre of New Jersey campus in North Brunswick. Offering incubator, intermediate and larger stand-alone space, the Technology Centre’s 75-acre campus in the heart of the biopharmaceutical corridor supports the facility needs of companies at every stage of their growth.
In May 2017, Lupin Limited, an India-based transnational pharmaceutical company, opened a 100,000-square-foot expansion of its manufacturing facility in Somerset. The new facility will focus on the manufacture of medicines for treatment of a variety of therapeutic areas.
In August, 2017, Modern Meadow, a company pioneering the creation of animal materials through biotechnology, announced it would be relocating its headquarters from Brooklyn and moving into a state-of-the-art laboratory and pilot manufacturing site at ON3, the campus in Nutley/Clifton that also will be home to the new Seton Hall-Hackensack Meridian School of Medicine. The New Jersey Economic Development Authority (NJEDA) awarded the company $32 million in Grow New Jersey tax credits over 10 years for the creation of 263 new jobs.
Sandoz Inc., the generic pharmaceuticals division of Switzerland-based Novartis, moved its U.S. corporate headquarters from West Windsor to Princeton in 2014, adding 70 jobs and retaining nearly 300. The project represented an estimated capital investment of $15.2 million. The EDA awarded Sandoz $9.1 million in Grow NJ incentives over 10 years to continue to grow in New Jersey.
SOLARIS PHARMA CORP.
In May 2017, Solaris Pharma Corp. more than tripled its footprint at the New Jersey Center of Excellence in Bridgewater. The pharmaceutical company, which will now occupy an entire floor at the 110-acre campus, is engaged in the development of topical and transdermal pharmaceutical products.
SPECTRUM PHARMACY PRODUCTS
In May 2017, Spectrum Pharmacy Products, a global manufacturer and distributor of pharmaceutical compounding chemicals, equipment and supplies opened its new Spectrum Pharmacy Institute, a 42,000-square-foot manufacturing, distribution and compounding training center in New Brunswick. 15,000 square feet of the Spectrum Pharmacy Institute is dedicated to continuing education classrooms, as well as advanced laboratories for hands-on, best practices compounding training.
In July 2016, Teligent, Inc., a specialty generic pharmaceutical company, broke ground for the expansion of its manufacturing and research and development complex in Buena Vista Township. The expansion will increase the facility’s footprint by more than 75,000 square feet, a 200% increase to its current facility. The facility is scheduled for completion in late 2017.